AGP Executive Report
Last update: 4 hours agoRoche: The US FDA approved Enspryng as an at-home injection for thyroid eye disease, giving patients a new treatment option from the Swiss drugmaker. Swiss Flu Season: Flu vaccines are delayed, but no shortage is expected, according to a report on the upcoming season. Child Poverty: Nearly one in five children in Switzerland is at risk of poverty, highlighting a social challenge with potential consequences for families’ wellbeing. Novartis: The Swiss pharmaceutical company ended a mid-stage trial of Fabhalta for a serious kidney condition.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.